The Age at Onset of LRRK2 p. Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin
Annals of Neurology · 2026-06 · 99 (6) · 1394-1404
DOI: 10.1002/ana.78181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 24.02.2026. Verfasst von Theresa Lüth und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation, Aligning Science Across Parkinson's (ASAP), German Research Foundation (DFG), RU ProtectMove.
Abstract (Originalsprache)
Objectives
The objective of this study was to elucidate differences in the cumulative incidence of Leucine‐rich repeat kinase 2 (LRRK2) p.Gly2019Ser ‐ related Parkinson's disease (PD; LRRK2 ‐PD) between ancestries and countries.
Methods
We included 922 unrelated p.Gly2019Ser variant carriers (affected = 762 and unaffected = 160) from the Global Parkinson's Genetics Program (GP2) in addition to cohorts recruited from the Israeli Ashkenazi Jewish and Tunisian Arab‐Berber population. Cox proportional hazard models were applied to examine differences in cumulative incidence across ancestry groups and countries. All analyses were adjusted for biological sex and were exploratory.
Results
The median age at onset (AAO) of LRRK2 ‐PD was 5 years younger in the North African (hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.18–1.86, p = 7.0 × 10 −4 ) compared with the European ancestry group. In contrast, the median AAO was 5 years older in the Ashkenazi Jewish (HR = 0.61, 95% CI = 0.50–0.75, p = 4.0 × 10 −6 ) compared with the European ancestry group. Additionally, patients from Israel (HR = 1.59, 95% CI = 1.30–1.39, p = 4.0 × 10 −6 ) and Tunisia (HR = 2.57, 95% CI: 2.16–3.06, P < 2.0 × 10 −16 ) had a median 5‐year and 10‐year younger AAO compared with patients from the United States, respectively. Last, when focusing only on individuals with an Ashkenazi Jewish background, patients from Israel still had a younger AAO than those from the United States (HR = 1.82, 95% CI = 1.48–2.24, p = 1.5 × 10 −8 ). Analogously, assessing only patients from the United States, the Ashkenazi Jewish ancestry group still had an older AAO than the European ancestry group (HR = 0.51, 95% CI = 0.39–0.67, p = 1.3 × 10 −6 ).
Interpretation
Our results provide evidence that a person's genetic ancestry and country of origin are associated with the AAO of LRRK2 ‐PD. This highlights the potential impact of both genetic and environmental factors on LRRK2 ‐PD AAO. ANN NEUROL 2026;99:1394–1404
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
- Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.
- Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
- Institute of Medical Informatics and Statistics, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
- Statistical Genetics and Clinical Studies, Medical Faculty, Health and Medical University Erfurt, Erfurt, Germany.
- Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
ORCID-Profile: Theresa Lüth, Sebastian Sendel, Alastair J Noyce, Matthew Farrer
Förderung
- Michael J. Fox Foundation
- Aligning Science Across Parkinson's (ASAP)
- German Research Foundation (DFG), RU ProtectMove
- DFG Heisenberg Grant
- Michael J. Fox Foundation for Parkinson's Research
Zitieren
APA
Lüth, T., Laabs, B. H., Sendel, S., König, I. R., Caliebe, A., Noyce, A. J., Screven, L. A., Bardien, S., Farrer, M., Hentati, F., Amouri, R., Klein, C., Sassi, S. B., Trinh, J., & Global Parkinson's Genetics Program (GP2) (2026). The Age at Onset of LRRK2 p. Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin. Annals of Neurology, 99(6), 1394-1404. https://doi.org/10.1002/ana.78181
Vancouver
Lüth T, Laabs BH, Sendel S, König IR, Caliebe A, Noyce AJ, et al. The Age at Onset of LRRK2 p. Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin. Annals of Neurology. 2026;99(6):1394-1404. doi:10.1002/ana.78181
BibTeX
@article{Lth2026,
author = {Lüth, Theresa and Laabs, Björn-Hergen and Sendel, Sebastian and König, Inke R and Caliebe, Amke and Noyce, Alastair J and Screven, Laurel A and Bardien, Soraya and Farrer, Matthew and Hentati, Faycel and Amouri, Rim and Klein, Christine and Sassi, Samia Ben and Trinh, Joanne and Global Parkinson's Genetics Program (GP2), Global Parkinson's Genetics Program (GP2)},
title = {The Age at Onset of LRRK2 p. Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin},
journal = {Annals of Neurology},
year = {2026},
volume = {99},
number = {6},
pages = {1394--1404},
doi = {10.1002/ana.78181}
}
EUVIMED